249 related articles for article (PubMed ID: 25200342)
1. Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes.
Edwards SK; Baron J; Moore CR; Liu Y; Perlman DH; Hart RP; Xie P
J Hematol Oncol; 2014 Sep; 7():56. PubMed ID: 25200342
[TBL] [Abstract][Full Text] [Related]
2. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
3. Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.
Edwards SK; Han Y; Liu Y; Kreider BZ; Liu Y; Grewal S; Desai A; Baron J; Moore CR; Luo C; Xie P
Leuk Res; 2016 Feb; 41():85-95. PubMed ID: 26740054
[TBL] [Abstract][Full Text] [Related]
4. Expression and function of a novel isoform of Sox5 in malignant B cells.
Edwards SK; Desai A; Liu Y; Moore CR; Xie P
Leuk Res; 2014 Mar; 38(3):393-401. PubMed ID: 24418753
[TBL] [Abstract][Full Text] [Related]
5. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic profiling of splenic B lymphomas spontaneously developed in B cell-specific TRAF3-deficient mice.
Xie P; Moore CR; Swerdel MR; Hart RP
Genom Data; 2014 Dec; 2():386-388. PubMed ID: 25419513
[TBL] [Abstract][Full Text] [Related]
7. Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms.
Moore CR; Edwards SK; Xie P
J Cancer Sci Ther; 2015 Feb; 7(2):67-74. PubMed ID: 25960828
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Fission Factor Is a Novel Interacting Protein of the Critical B Cell Survival Regulator TRAF3 in B Lymphocytes.
Liu Y; Gokhale S; Jung J; Zhu S; Luo C; Saha D; Guo JY; Zhang H; Kyin S; Zong WX; White E; Xie P
Front Immunol; 2021; 12():670338. PubMed ID: 34745083
[TBL] [Abstract][Full Text] [Related]
9. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.
Whillock AL; Mambetsariev N; Lin WW; Stunz LL; Bishop GA
Sci Rep; 2019 Sep; 9(1):12884. PubMed ID: 31501481
[TBL] [Abstract][Full Text] [Related]
10. Elevated Choline Kinase α-Mediated Choline Metabolism Supports the Prolonged Survival of TRAF3-Deficient B Lymphocytes.
Gokhale S; Lu W; Zhu S; Liu Y; Hart RP; Rabinowitz JD; Xie P
J Immunol; 2020 Jan; 204(2):459-471. PubMed ID: 31826940
[TBL] [Abstract][Full Text] [Related]
11. TRAF3 deficiency promotes metabolic reprogramming in B cells.
Mambetsariev N; Lin WW; Wallis AM; Stunz LL; Bishop GA
Sci Rep; 2016 Oct; 6():35349. PubMed ID: 27752131
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of the adenomatous polyposis coli (Apc) and mutated in colorectal cancer (Mcc) genes in mouse lung neoplasia.
Oreffo VI; Robinson S; You M; Wu MC; Malkinson AM
Mol Carcinog; 1998 Jan; 21(1):37-49. PubMed ID: 9473770
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1.
Contreras JR; Palanichamy JK; Tran TM; Fernando TR; Rodriguez-Malave NI; Goswami N; Arboleda VA; Casero D; Rao DS
Oncotarget; 2015 May; 6(13):11023-37. PubMed ID: 25906746
[TBL] [Abstract][Full Text] [Related]
14. Troy, a tumor necrosis factor receptor family member, interacts with lgr5 to inhibit wnt signaling in intestinal stem cells.
Fafilek B; Krausova M; Vojtechova M; Pospichalova V; Tumova L; Sloncova E; Huranova M; Stancikova J; Hlavata A; Svec J; Sedlacek R; Luksan O; Oliverius M; Voska L; Jirsa M; Paces J; Kolar M; Krivjanska M; Klimesova K; Tlaskalova-Hogenova H; Korinek V
Gastroenterology; 2013 Feb; 144(2):381-391. PubMed ID: 23142137
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
den Hollander J; Rimpi S; Doherty JR; Rudelius M; Buck A; Hoellein A; Kremer M; Graf N; Scheerer M; Hall MA; Goga A; von Bubnoff N; Duyster J; Peschel C; Cleveland JL; Nilsson JA; Keller U
Blood; 2010 Sep; 116(9):1498-505. PubMed ID: 20519624
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
17. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
18. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
19. miR-17-92 functions as an oncogene and modulates NF-κB signaling by targeting TRAF3 in MGC-803 human gastric cancer cells.
Liu F; Cheng L; Xu J; Guo F; Chen W
Int J Oncol; 2018 Nov; 53(5):2241-2257. PubMed ID: 30226589
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.
Shen RR; Ferguson DO; Renard M; Hoyer KK; Kim U; Hao X; Alt FW; Roeder RG; Morse HC; Teitell MA
Blood; 2006 Sep; 108(6):1991-8. PubMed ID: 16728701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
